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Abstract
Holocarboxylase synthetase (HCS) catalyzes the binding of the vitamin biotin to carboxylases and
histones. Carboxylases mediate essential steps in macronutrient metabolism. For example, propionyl-
CoA carboxylase (PCC) catalyzes the carboxylation of propionyl-CoA in the metabolism of odd-
chain fatty acids. HCS comprises four putative domains, i.e., the N-terminus, the biotin transfer/ATP
binding domain, a putative linker domain, and the C-terminus. Both N- and C-termini are essential
for biotinylation of carboxylases by HCS, but the exact functions of these two domains in enzyme
catalysis are unknown. Here we tested the hypothesis that N- and C-termini play roles in substrate
recognition by HCS. Yeast-two-hybrid (Y2H) assays were used to study interactions between the
four domains of human HCS with p67, a PCC-based polypeptide and HCS substrate. Both N- and
C-termini interacted with p67 in Y2H assays, whereas the biotin transfer/ATP-binding and the linker
domains did not interact with p67. The essentiality of N- and C-termini for interactions with
carboxylases was confirmed in rescue experiments with mutant Saccharomyces cerevisiae, using
constructs of truncated human HCS. Finally, a computational biology approach was used to model
the 3D structure of human HCS and identify amino acid residues that interact with p67. In silico
predictions were consistent with observations from Y2H assays and yeast rescue experiments, and
suggested docking of p67 near Arg508 and Ser515 within the central domain of HCS.
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Introduction
Biotin is a water-soluble vitamin that serves as a coenzyme for acetyl-CoA carboxylases 1 and
2 (ACC1 and ACC2), 3-methylcrotonyl-CoA carboxylase (MCC), pyruvate carboxylase (PC),
and propionyl-CoA carboxylase (PCC). These carboxylases play pivotal roles in human
metabolism [1]. Both ACC1 and ACC2 catalyze the incorporation of bicarbonate into malonyl-
CoA, a key regulatory step in fatty acid synthesis (ACC1) and mitochondrial fatty acid transport
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(ACC2). 3-Methylcrotonyl-CoA carboxylase is involved in the catabolism of the branched-
chain amino acid leucine. Pyruvate carboxylase catalyzes the carboxylation of pyruvate to
produce oxaloacetate in gluconeogenesis. Finally, PCC is involved in the conversion of
propionyl-CoA to methylmalonyl-CoA in the metabolism of odd-chain fatty acids.
Biotin is also attached covalently to at least 11 distinct lysine residues in histones H2A, H3,
and H4 [2-5]. Biotinylation of histones participates in the cross-talk among various histone
modifications and in gene regulation [6-9]. For example, K12-biotinylated histone H4 co-
localizes with K9-dimethylated histone H3 in pericentrometric heterochromatin and repressed
genes [9,10]. In addition to its role in heterochromatin structures and gene repression,
biotinylation of histone H4 appears to participate in the cellular response to DNA damage
[11], and in the repression of retrotransposons [12].
The attachment of biotin to carboxylases and histones is mediated by holocarboxylase
synthetase (HCS, EC 6.3.4.10). The open reading frame of full-length HCS encodes 726 amino
acids [13] but the existence of at least three splicing variants (76, 82, and 86 kDa) has been
confirmed [14]. HCS has been detected in cytoplasm, mitochondria, cell nuclei, and the nuclear
lamina [14,15].
BirA is the microbial ortholog of HCS and its investigation has provided valuable insights into
HCS structure and catalysis, and the amino acid sequences in both proteins are 21% identical.
The three-dimensional structure of E. coli BirA has been solved by x-ray crystallography
[16] and consists of three domains: an N-terminal domain, a central domain, and a C-terminal
domain [17]. The central domains in BirA and HCS contain binding sites for both ATP and
biotin and their functions in catalysis are well understood [18-20]. In contrast, the amino acid
sequence of the N-termini in BirA and human HCS are fairly distinct, thereby preventing
predictions of HCS structure solely based on analogies to the BirA N-terminus. The N-terminus
of BirA contains 60 amino acid residues, whereas that of human HCS is up to 446 amino acids
long, depending on splicing. It has been speculated that the N-terminal domain in human HCS
might play roles in gene regulation, protein-protein interactions (PPI), and substrate recognition
[14,20]. The C-terminal domain in BirA is essential for biotinyl ligase activity [17,20] and
might also participate in substrate recognition [17]. It remains to be determined whether the
C-terminus in HCS plays a similar role, given that BirA and HCS have distinct biotinylations
targets: biotin carboxyl carrier protein for BirA, and five distinct carboxylases and three major
classes of histones for HCS.
The three-dimensional structure of HCS has not yet been determined. Here we provide novel
insights into the structure of human HCS and the functions of its domains by using molecular
modeling approaches, yeast-two-hybrid (Y2H) assays, and rescue experiments in yeast
mutants.
Materials & Methods
Cloning of p67 and fusion to a Gal4 activation domain
The polypeptide p67 comprises the 67 C-terminal amino acids in human PCC (GenBank
accession #AAA60035), including the biotin-binding site K669 [18]. p67 is a well-established
substrate for studies of HCS [18,20]. Here we used p67 to investigate domain-domain
interactions between substrate and HCS. p67 was cloned from human liver cDNA into the
cloning vector pSTBlue (Novagen; San Diego, CA) by using forward primer 5′-
gaattcctgcgttccccgatg-3′ and reverse primer 5′-ctgctcgtggagctggaatgaggatcc-3′. The resulting
plasmid was named “p67-pSTBlue.” p67-pSTBlue was sequenced in the DNA core facility of
the University of Nebraska-Lincoln, and digested using EcoRI and BamHI. The insert encoding
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p67 was fused to a Gal4 activation domain, using vector pGADT7 (Clontech; Mountain View,
CA); this plasmid was named “pGADT7-p67” and its identity was confirmed by sequencing.
Cloning of HCS and its different domains into a Gal4 binding domain vector
Plasmid pUC-CAGG encodes full-length human HCS (GenBank accession #D23672) and was
kindly provided by Y. Suzuki (Department of Biochemical Genetics, Tohoku University
School of Medicine, Sendai, Japan) [13]. Using pUC-CAGG as a template, full-length human
HCS was PCR amplified using the following primers: 5′-actgaattcctcatggaagatagactccac-3′
(forward) and 5′-actgtcgacttaccgccgtttggggaggatg-3′ (reverse). The PCR product was purified,
digested with EcoRI and SalI, and sub-cloned directly into a linearized pGBKT7 vector
(Clontech, cat.# K1612-1) to produce plasmid “pGBKT7-HCS.” Plasmid identity was
confirmed by sequencing.
In silico analysis of human HCS by using the Pfam database [21] predicted four major HCS
domains (Fig. 1). The following HCS domains were PCR amplified for studies of interactions
between p67 in Y2H assays: the N-terminal domain (M1-F446) was amplified using primers
5′-catggaggccgaattaatggaagatagactccac-3′ (forward) and 5′-
gccgctgcaggtcgaccgaaggcctccatgttggtc-3′ (reverse); the biotin transfer/ATP binding (central)
domain (F471-S575) was amplified using primers 5′-ccatggaggccgaattatttgccgaagtgacccc-3′
(forward) and 5′-gccgctgcaggtcgagcgtcactgtaataaatatc-3′ (reverse); the putative linker domain
(T610-V668) was amplified using primers 5′-catggaggccgaattaaccatctgcatcaacg-3′ (forward)
and 5′-gccgctgcaggtcgaccgtggacccagtatcgg-3′ (reverse); and the C-terminal domain (H669-
R718) was amplified using primers 5′-catggaggccgaattccacagtggtcagcaagtc-3′ (forward) and
5′-gccgctgcaggtcgacctctcagcatgtcgaaggag-3′ (reverse) primers. PCR products were fused to a
Gal4 BD, using pGBKT7 vector that was linearized with EcoRI and SalI and the infusion
cloning system (Clontech, cat.# 631774); the four plasmids are denoted pGBKT7-HCS1-446,
pGBKT7-HCS471-575, pGBKT7-HCS610-668, and pGBKT7-HCS669-718. Identities of clones
were verified by sequencing.
Functional complementation of pGBKT7-HCS and Saccharomyces cerevisiae biotin protein
ligase1 (BPL1)
We used a functional complementation approach to verify that HCS was correctly folded and
retained its biotin ligase activity when fused to Gal4 BD. The BPL1 gene codes for the HCS
ortholog BPL1 in Saccharomyces cerevisiae. The open reading frame of BPL1 plus 500 bp 5′
and 500 bp 3′ flanking sequences was PCR-amplified as a SalI-NotI fragment. This SalI-
BPL1-NotI fragment was inserted into pRS416 (CEN-ARS-URA3), resulting in plasmid
pLO70. The sequence of the BPL1 gene in pLO70 was confirmed by DNA sequencing. All
yeast strains used in this work were derived from W303-1B (MATα ade2-1 can1-100
his3-11,15 leu2-3,112 trp1-1 ura3-1). W303-1B was transformed to Ura+ with plasmid pLO70,
making strain YLO48 (W303-1B + pLO70).
Strain YLO49 (W303-1B, bpl1 Δ::kanMX + pLO70) was made geneticin-resistant by
transforming YLO48 with a PCR-generated fragment composed of kanMX flanked by 5′ and
3′ flanking sequences of the BLP1 coding sequence. YLO49 was transformed to Trp+ with
pGBKT7 (Gal4 BD), pGBKT7-HCS (Gal4 BD fused with full-length HCS), pGBKT7-
HCS1-446 (Gal4 BD fused with the HCS N-terminal domain), pGBKT7-HCS471-575 (Gal4 BD
fused with the HCS central domain), pGBKT7-HCS610-668 (Gal4 BD fused with the HCS linker
domain), and pGBKT7-HCS669-718 (Gal4 BD fused with the HCS C-terminal domain) to
produce strains YLO50 (W303-1B, bpl1 Δ::kanMX + pLO70 + pGBKT7), YLO51 (W303-1B,
bpl1 Δ::kanMX + pLO70 + pGBKT7-HCS), YLO52 (W303-1B, bpl1 Δ::kanMX + pLO70 +
pGBKT7-HCS1-446), YLO53 (W303-1B, bpl1 Δ::kanMX + pLO70 + pGBKT7-HCS471-575),
YLO54 (W303-1B, bpl1 Δ::kanMX + pLO70 + pGBKT7-HCS610-668), and YLO55
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(W303-1B, bpl1 Δ::kanMX pLO70 + pGBKT7-HCS669-718) respectively. Ten-fold serial
dilutions of three independent clones of each strain were plated on SC (synthetic complete),
SC minus tryptophan (SC-Trp) and SC+FOA plates and grown for three days.
In additional rescue studies, the following two truncated forms of HCS were used. HCS lacking
the N-terminal domain (M1-F446) was PCR amplified using the pUC-CAGG plasmid as a
template and the following primers: 5′-tggaggaattcatgtcatcagaacatttcaacttag-3′ (forward) and
5′-tatatgtcgaccttaccgccgtttggg-3′ (reverse). The PCR products were cloned into pCR-Blunt II-
TOPO vector (Invitrogen; Carlsbad, CA) before digestion with EcoRI and SalI and sub-cloning
into the pGBKT7 vector for fusion to a Gal4 BD; the resulting vector is denoted pGBKT7-
HCS_Ndel. A HCS fusion construct lacking the C-terminal domain (H669-R718) was generated
as described for pGBKT7-HCS_Ndel, using the following primers: 5′-
tggaggaattcatggaagatagactccacatggataatggactggtaccccaaaagattg-3′ (forward) and 5′-
tatatgtcgaccttaccgccgtttggggaggatgaggttgacccagtatcggtaataaag-3′ (reverse). This plasmid is
denoted pGBKT7-HCS_Cdel. Plasmids pGBKT7-HCS_Ndel and pGBKT7-HCS_Cdel were
used to make strains YLO56 (W303-1B, bpl1 Δ::kanMX + pLO70 + pGBKT7-HCS_Ndel)
and YLO57 (W303-1B, bpl1 Δ::kanMX + pL070 + pGBKT7-HCS_Cdel) to determine whether
BPL1 mutants could be rescued by N- and C-truncated HCS.
Characterization of interactions between p67 and HCS
Interactions between p67 and HCS were investigated using Y2H assays by co-transforming
Saccharomyces cerevisiae strain AH109 (Clontech, cat.# 630444) with various HCS-Gal4 BD
fusion plasmids and pGADT7-p67. After transformation, yeast was plated on SD/-Leu, -Trp,
+Kan and incubated until colonies became visible. Colonies were then re-suspended in 10 μL
YPDA broth and spotted on SD/-Leu, -Trp, -His, -Ade, + Kan and incubated at 30°C in inverted
position for 21 days. Plates were monitored daily for appearance of colonies; strong interactors
are visible earlier than weak interactors. After 21 days of monitoring, the recovered clones
were streaked out on SD/-Leu, -Trp, -His, -Ade, + Kan supplemented with X-α-gal (200 μl of
2 mg/ml in DMF) to screen for LacZ gene activation by X-alpha-Gal assay (Clontech, cat.#
630407).
Modeling of HCS and p67 interactions by computational biology
The 3D structure of full-length human HCS was modeled using PHYRE [22]. The 3D model
of human HCS spanning amino acid sequences 393 through 715 was based on the crystal
structure of E. coli BirA [23]. The sequences of BirA and human HCS have a FASTA E-value
of 4.2e-31 which is considered significant [24]. Similar results were obtained by using the 3D-
JIGSAW server [25].
A 3D-model of amino acids 1 to 66 in p67 was obtained by 3D-JIGSAW using biotin carboxyl
carrier protein from Pyrococcus horikoshi as a template [26]. The 3D structure of p67 was
independently confirmed by PHYRE for amino acids 2 to 65.
In order to assess the interactions between human HCS and p67, the docking of both proteins
was analyzed by PATCHDOCK and further refined by FireDock [27]. PATCHDOCK
calculates the spatial shape complementation of two structures and provides a list of potential
complexes. In our docking calculation, protein surfaces were treated as if they were facing an
aqueous phase. The likelihood of unrealistic predictions was further decreased by conducting
analogous docking calculations for BirA and its substrate biotin carboxyl carrier protein [23].
Only docking interactions that were similar for HCS and p67 versus BirA and biotin carboxyl
carrier protein were considered for further analyses. Data from docking models were refined
using data from site-directed mutagenesis experiments with BirA [17]. 3D modeling of HCS/
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p67 interactions was completed by visual inspection of representations generated by PyMol
[28] and Deep View [29].
Results
Functional characterization of the N and C termini of HCS
Full-length HCS interacted with p67 in Y2H (Fig. 2). Colonies became visible on plates after
14-15 days of culture, consistent with transient interactions typically observed for enzymes
and their substrates [30,31]. Of the four individual HCS domains tested, only M1-F446 (N-
terminus) and H669-R718 (C-terminus) produced detectable interactions with p67. The C-
terminal domain interacted with p67 more strongly than the N-terminal domain. In response
to transformation with pGBKT7-HCS669-718, yeast colonies became visible on plates after only
4-5 days of culture. In response to transformation with pGBKT7-HCS1-466, yeast colonies
became visible on plates after 8-9 days of culture. The observation that individual domains
interacted stronger than the full length HCS might be explained by the fact that amino acids
involved in establishing the HCS-p67 interaction were exposed and readily accessible in
constructs coding for individual domains.
Biological activity of hHCS and HCS domain deletions in yeast
Human HCS is biologically active in yeast. Deletions in YDL141W (the gene coding for BPL1)
are known to be lethal for Saccharomyces cerevisiae. In our studies we transformed BPL1
mutants with the plasmid pGBKT7-HCS in which human HCS is fused to a Gal4 BD.
Transformation with pGBKT7-HCS rescued BPL1 mutants, whereas non-transformed cells
died (Fig. 3). This is consistent with the notion that hHCS functionally complements its yeast
ortholog BPL1, and that results from Y2H assays are valid. Transformation of BPL1 mutant
yeast with individual HCS domains (pGBKT7-HCS1-446, pGBKT7-HCS471-575, pGBKT7-
HCS610-668, and pGBKT7-HCS669-718) or truncated forms of HCS (pGBKT7-HCS_Ndel and
pGBKT7-HCS_Cdel) was not sufficient to rescue the mutants. This is consistent with the
theory that both N-terminal and C-terminal domains in HCS are crucial for substrate
recognition.
3D modeling of HCS
We modeled the 3D structure of human HCS by using the published structure of BirA from
E. coli as a template [32]. The proposed structure of HCS spans amino acids 393 to 715,
corresponding to the N-terminal, central, and C-terminal domains in BirA. Only a small
fragment of the N-terminal domain in human HCS was included in our model because of the
absence of a conserved sequence in the BirA template. The overall root mean square deviation
(RSMD) between the predicted HCS structure and the BirA template was 3.2 Å, but it improved
to 1.2 Å for the biotin-binding site and the HCS region spanning Thr489 to Asn606. The
comparably large RSMD for the overall model was caused by an insertion in human HCS,
predicting an α- helix in the region from Asn606 to Asn621 compared to a loop in the region
from Asn134 to Tyr141 in BirA.
Human HCS and BirA were superimposed to identify conserved amino acid residues that are
likely to be important for HCS catalysis. In the central domain of human HCS, the Arg508-
Ser515 loop corresponded to the biotin binding site (Arg118-Ser125) in BirA. Our model
predicted the existence of a short helix in HCS (Asn606-Asn621), in which valine substituted
for tryptophan in the corresponding helix in BirA (Met211-Trp223). Valine668 in the linker
region of HCS corresponded to Ile272 in BirA. Histidine-675 and Lys683 in the C-terminal
domain of HCS corresponded to Lys277 and Lys283, respectively, in BirA. Although Arg718
in HCS was not included in structure predictions, sequence comparisons suggest that this
residue might correspond to Arg317 in BirA.
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Next, we predicted the structure of the HCS substrate p67 for subsequent docking calculations.
For structure predictions, we used the BirA substrate biotin carboxyl carrier protein as a
template. The FASTA E-value for p67 and the biotin carboxyl carrier protein was 4e-19 with
an excellent RSMD permitting reliable prediction of the p67 structure at the 0.3 Å level of
resolution. In biotin carboxyl carrier protein, Glu119 and Glu147 are important for
biotinylation by BirA [17]. These residues are conserved as Glu29 and Glu58 in p67 (Glu691
and Glu720 in PCC).
The above observations are consistent with the conservation of individual amino acids and
entire domains in biotin protein ligases and their substrates. Our docking calculations suggested
that the p67 molecule spatially complemented the cleft along Arg588, Lys579, Ser515
including a potential biotin binding site in human HCS (Fig. 4). Arg508 and Ser515 in human
HCS appear to be equally important for binding of p67.
Discussion
HCS has a broad substrate specificity and interacts with at least with five different carboxylases
and up to five classes of histones [15,33-35]. Carboxylases and histones do not share any
apparent sequence similarities, raising the question of how HCS recognizes its biotinylation
targets. While the preparation of pure and bioactive recombinant HCS and its characterization
by X-ray crystallography are imminent, no such data are publicly available yet. In the absence
of such data, is a reasonable approach to make predictions of HCS structure and substrate
interaction based on analogies with BirA. This paper offers novel insights into the structure of
HCS and its potential interactions with the p67 substrate by using a unique combination of in
silico modeling, Y2H assays, and yeast rescue studies. A similar computational approach was
recently used to predict the structure of biotinidase, another enzyme involved in biotin
metabolism [36].
This study makes a number of valuable contributions towards the elucidation of HCS structure
and catalysis. First, this study provides experimental evidence that the N-terminus domain of
HCS participates in p67 binding, based on data from Y2H assays. This is in agreement with
previous studies [13,14,20], which suggest that amino acids 128 to 446 in the HCS N-terminus
are important for biotin ligase activity. The specific roles of amino acids 128 to 446 were not
elucidated in these previous studies of HCS catalysis.
Second, this study confirms previous theories by Chapman-Smith et al. that the C-terminus of
HCS is important for substrate recognition and for the initiation of the biotin transfer process
[17]. Those investigators showed that the C-terminal domain of BirA is essential for biotin
carboxyl carrier protein. Likewise, truncation or removal of the C-terminus in human HCS
abolishes biotinyl ligase activity of HCS towards biotin carboxyl carrier protein and p67 [20].
Third, our studies demonstrate that both the central and linker domains in HCS do not
participate in substrate recognition. This conclusion is based on the absence of detectable
interactions between these two domains and p67 in Y2H assays.
Fourth, our laboratory and perhaps others are heavily invested in the identification of proteins
that interact with HCS in order to target the enzyme to distinct regions in chromatin [37-39].
Initial screens for HCS-interacting proteins are based on Y2H assays. Our observation that
human HCS can rescue BPL1 mutant yeast suggests that human HCS in Y2H is fully functional.
Thus, the risk of encountering false positive clones in Y2H assays is reasonably small.
Fifth, this paper reveals potential docking sites for p67 in human HCS, i.e., the cleft along
Arg588, Lys579, and Ser515, which act in concert with Arg508 and Ser515. Our prediction
for putative docking sites is based on X-ray crystallography data from studies of BirA and
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biotin carboxyl carrier protein. It is noteworthy that the R508W mutation is one of the most
common HCS mutations found in human patients of various ethnicities [40]. Patients carrying
this mutations respond exceptionally well to biotin supplementation, consistent with a role of
this residue in the binding of substrate and biotin [41].
Sixth, our model also reveals the existence of flexible loops in human HCS, e.g., loops Glu412-
Gln417, Asn608-Thr618, Gly701-Val704, and the Phe487-Pro490 turn (Fig. 5). These loops
(in particular Gly701-Val704) confer a comparably great degree of structural flexibility and,
thus, are of particular interest in the light of the fairly broad substrate specificity of HCS
(various carboxylases and histones).
Seventh, our in silico model highlighted one arginine residue (R718) in the C-terminal domain
of HCS that might have a major role in enzyme-substrate recognition. Our model predicts that
R718 likely corresponds to the highly conserved R317 in BirA, which is known to be critical
for substrate recognition [17]. In previous studies it has been suggested that R317 in BirA
corresponds to R725 rather than R718 in HCS [17]. We do not believe this to be the case, given
that that a construct lacking R725 physically interacted with p67 in our Y2H assays. Our
modeling studies identified another conserved positively charged residue (His675) that might
be important for substrate alignment. Previous studies aligned His675 with a lysine residue
(K277) in BirA, and showed that K277 is critical for the correct alignment of biotin carboxyl
carrier protein within the active site of BirA [17].
We recognize moderate uncertainties associated with this study. For example, we acknowledge
that a simple interaction between single amino acid residues and charged surfaces does not
provide sufficient parameters to build a model for enzyme-substrate orientation. However, if
coupled with the exploration of the tertiary fold orientation, one can speculate as to which
amino acid residues in HCS might be critical for substrate binding in analogy to BirA studies
[42,43].
In conclusion, this paper provides important insights into the structure of human HCS. Our
laboratory is currently pursuing the characterization of HCS by X-ray crystallography to
address some of the uncertainties associated with the model outlined here.
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Abbreviations
ACC, acetyl-CoA carboxylase
Ade, adenine
Arg, arginine
Asn, asparagine
BPL1, biotin protein ligase1
FOA, 5-fluorouracil-6-carboxylic acid monohydrate
Gal4 BD, Gal4 DNA binding domain
Glu, glutamic acid
HCS, holocarboxylase synthetase
His, histidine
Kan, kanamycin
Leu, leucine
Lys, lysine
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MCC, 3-methylcrotonyl-CoA carboxylase
PC, pyruvate carboxylase
PCC, propionyl-CoA carboxylase
PPI, protein-protein interactions
SD, synthetic defined
Ser, serine
Thr, threonine
Trp, tryptophan
Tyr, tyrosine
Y2H, yeast two hybrid
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Figure 1.
Predictions of four domains in human HCS: N-terminal domain (M1-F446); central domain
“CD” (F471-S575) containing biotin transfer and ATP-binding sites; linker domain “L” (T610-
V668); and C-terminal domain “CT” (H669-R718). The domains are drawn to scale.
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Figure 2.
The N- and C-termini in human HCS interact with p67 in Y2H. N-terminal domain (NT),
central domain (CD), linker domain (L), C-terminal domain (CT), and full-length HCS (FL-
HCS) were investigated. The interaction between p53 and T antigen was used as positive
control (CONT). Panel A: plate layout. Panel B: Growth of the yeast host strain AH109 was
transformed with Gal4BD-HCS domains and Gal4AD-p67 on SD/-Leu,-Trp, +Kan medium
to confirm co-transformation with both plasmids. Panel C: Activation of reporter genes in
AH109 yeast caused by HCS-p67 interactions.
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Figure 3.
Human HCS functionally complements biotin protein ligase (BPL1) in yeast. The YLO49
strain of S. cerevisiae was created by deleting the BPL1 gene; YLO49 yeast was transformed
using an empty Gal4 BD vector (YLO50) or a plasmid coding for human HCS fused to Gal4
BD (YLO51).
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Figure 4.
Human HCS contains two potential docking sites for p67 near the biotin (BIO) and ATP binding
sites. Two molecules of p67 are depicted as ribbon models and identified by using dotted
circles. Functionally important amino acid residues in the central domain and C-terminal
domain are highlighted in blue and green, respectively. Functionally important residues in p67
are depicted in red.
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Figure 5.
Human HCS contains flexible loops. The predicted 3D structure of human HCS (gray) was
imposed on the structure of BirA (pink) to reveal flexible loops (dotted circles). Functionally
important amino acid residues in HCS are highlighted.
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